Last reviewed · How we verify
Pyramax
At a glance
| Generic name | Pyramax |
|---|---|
| Also known as | pyronaridine-artesunate, pyronaridine artesunate, PA, ISTp-US-Py |
| Sponsor | Shin Poong Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults (PHASE1)
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults (PHASE1, PHASE2)
- Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso (PHASE3)
- Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations in Healthy Volunteers (PHASE1)
- Drug Interaction Study of Pyronaridine-artesunate & Metoprolol, & Redosing Study of Pyronaridine-artesunate (PHASE1)
- The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3) (PHASE3)
- Bioequivalence Trial of Pyronaridine Artesunate To-be-marketed Tablet to the Clinical Trial Reference Tablet (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pyramax CI brief — competitive landscape report
- Pyramax updates RSS · CI watch RSS
- Shin Poong Pharmaceutical Co. Ltd. portfolio CI